JPMorgan Chase is set to report first-quarter earnings – here’s what the Street expects

JPMorgan Chase is set to report first-quarter earnings – here’s what the Street expects


Jamie Dimon, chief executive officer of JPMorgan Chase & Co., speaks during the 2025 National Retirement Summit in Washington, DC, US, on Wednesday, March 12, 2025.

Al Drago | Bloomberg | Getty Images

JPMorgan Chase is scheduled to report first-quarter earnings before the opening bell Friday.

Here’s what Wall Street expects, according to LSEG:

  • Earnings: $4.61 a share
  • Revenue: $44.11 billion

JPMorgan Chase will be the first major U.S. bank to report earnings for the most recent quarter in a time of rising economic uncertainty.

Investors will want to know how consumers, businesses and corporations are faring after President Donald Trump escalated global trade tensions starting April 2.

Jamie Dimon, the longtime JPMorgan leader, said Wednesday that he thought aggressive tariff policies would likely trigger a recession. Trump on Wednesday lowered his proposed tariff rates on most countries, except China, for an initial period of 90 days.

While bank executives are sure to focus on the quarter, which ended before Trump’s so-called “Liberation Day” announcement last week, bank stocks have swung wildly on recession fears, making backward-looking discussions less relevant.

The lack of certainty in the business environment for many companies was expected to cast a pall over some investment banking activities, including IPO listings and merger advice.

But it was also expected to provide a good environment for Wall Street trading desks to print money.

Wells Fargo and Morgan Stanley are also expected to report Friday, with Goldman Sachs, Bank of America and Citigroup coming next week.

This story is developing. Please check back for updates.



Source

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says
Business

More than 20,000 people are taking Eli Lilly’s weight loss pill Foundayo, CEO says

More than 20,000 people have started taking Eli Lilly‘s GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday. The FDA approved Lilly’s once-daily pill Foundayo earlier this month, making it the second oral GLP-1 drug behind Novo Nordisk’s Wegovy pill. Investors have been closely tracking […]

Read More
Lawyers to the wealthy warn that AI legal advice comes with serious risks
Business

Lawyers to the wealthy warn that AI legal advice comes with serious risks

Displeased couple having problems during a meeting with their agent in the office. Skynesher | E+ | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Lawyer Tasha Dickinson said […]

Read More
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Business

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IMF) and World Bank Spring meetings in Washington, DC, US, on Friday, April 17, 2026. Aaron Schwartz | Bloomberg | Getty Images Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past […]

Read More